KalVista Pharmaceuticals

145 articles about KalVista Pharmaceuticals

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 05, 2023

  6/5/2023

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 40,000 shares of KalVista common stock on June 1, 2023 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)

  6/2/2023

  KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 European Academy of Allergy and Clinical Immunology Congress, taking place in Hamburg, Germany and virtually, from June 9-11.

• KalVista Pharmaceuticals to Present at Jefferies 2023 Global Healthcare Conference

  5/31/2023

  KalVista Pharmaceuticals, Inc. announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023 at 2:00 p.m. ET in New York, NY.

• KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference

  5/23/2023

  KalVista Pharmaceuticals, Inc. announced it will participate in a fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day virtual conference on Tuesday, May 30, 2023 at 10:55 a.m. ET.

• KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

  5/8/2023

  KalVista Pharmaceuticals, Inc. announced that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2023

  5/2/2023

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on May 1, 2023 as inducement material to such employee entering into employment with KalVista.

• KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

  4/27/2023

  KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedema Workshop taking place in Budapest, Hungary from May 4-7.

• KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

  4/12/2023

  KalVista Pharmaceuticals, Inc. announced it will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023 at 11:00 a.m. ET.

• KalVista Pharmaceuticals Reports Third Fiscal Quarter Results - March 9, 2023

  3/9/2023

  KalVista Pharmaceuticals, Inc . today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2023.

• KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

  2/27/2023

  KalVista Pharmaceuticals, Inc. today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.

• KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

  2/16/2023

  KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27.

• KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

  2/14/2023

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided multiple clinical trial and regulatory updates for its lead compound sebetralstat, as a potential oral on-demand therapy for HAE attacks.

• KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet

  2/10/2023

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks has been published in the international weekly medical journal, The Lancet.

• KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

  2/7/2023

  KalVista Pharmaceuticals, Inc. today presented three posters at the Western Society of Allergy, Asthma & Immunology 60th Annual Scientific Session in Kona, HI.

• KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

  2/3/2023

  KalVista Pharmaceuticals, Inc. today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thursday, February 16, 2023 at 8:40 a.m. ET.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2023

  2/2/2023

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on February 1, 2023 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

  1/5/2023

  KalVista Pharmaceuticals, Inc. announced the promotion of Ben Palleiko, the Company’s current Chief Business Officer and Chief Financial Officer, to the additional title of President.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 4, 2023

  1/4/2023

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 1,000 shares of KalVista common stock on January 3, 2023 as inducement material to such employee entering into employment with KalVista.

• KalVista Pharmaceuticals Reports Second Fiscal Quarter Results - December 8, 2022

  12/8/2022

  KalVista Pharmaceuticals, Inc. today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2022

  12/5/2022

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 2,000 shares of KalVista common stock on December 1, 2022 as inducement material to such employee entering into employment with KalVista.